Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

Novel strategy for three-dimensional fragment-based lead discovery.

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Fragment Databases from Screened Ligands for Drug Discovery (FDSL-DD).

Fragment-based strategy for structural optimization in combination with 3D-QSAR

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery

Expanding medicinal chemistry into 3D space: metallofragments as 3D scaffolds for fragment-based drug discovery

In silico construction of a focused fragment library facilitating exploration of chemical space**

Evolutions in Fragment-Based Drug Design: the Deconstruction-Reconstruction Approach.

Fragment Informatics and Computational Fragment‐Based Drug Design: an Overview and Update

Design and Synthesis of 56 Shape‐Diverse 3D Fragments

Application of Fragment-Based Drug Discovery to Versatile Targets

Using DNA-encoded Libraries of Fragments for Hit Discovery of Challenging Therapeutic Targets

Applications of “linkers” in Fragment-Based Drug Design

Fragment Virtual Screening Based on Bayesian Categorization for Discovering Novel VEGFR-2 Scaffolds

Process of Fragment-Based Lead Discovery—A Perspective from NMR

Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications

Recent progress on fragment-based drug design

From pixels to druggable leads: A CADD strategy for the design and synthesis of potent DDR1 inhibitors

Fragment-Based Ligand Generation Guided By Geometric Deep Learning On Protein-Ligand Structure